Elanco Animal Health (NYSE:ELAN) Director Acquires $236,800.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Paul Herendeen acquired 10,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were bought at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the purchase, the director owned 111,687 shares in the company, valued at approximately $2,644,748.16. This represents a 9.83% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Elanco Animal Health Stock Up 0.6%

Elanco Animal Health stock traded up $0.14 during midday trading on Monday, hitting $22.26. 22,463,632 shares of the stock were exchanged, compared to its average volume of 5,703,481. Elanco Animal Health Incorporated has a 52-week low of $16.89 and a 52-week high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The business’s 50-day moving average price is $24.70 and its 200-day moving average price is $24.08. The stock has a market capitalization of $11.12 billion, a price-to-earnings ratio of -54.29, a price-to-earnings-growth ratio of 1.32 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Institutional Trading of Elanco Animal Health

Several institutional investors and hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC boosted its holdings in Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Elanco Animal Health in the second quarter worth $38,000. Root Financial Partners LLC raised its position in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new stake in Elanco Animal Health during the fourth quarter valued at $41,000. Finally, Torren Management LLC bought a new stake in Elanco Animal Health during the fourth quarter valued at $46,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ELAN. KeyCorp lifted their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday. Citigroup boosted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, UBS Group lifted their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.